As the in vivo results in Figure 5F–I, HNRNPAB silencing reversed the increase of PMN‐MDSCs and the reduction of CD8+ T cells, and recovered the tumor growth caused by tRF‐22 overexpression. This evidence concerns the gene HNRNPAB and neoplasm.